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Abstract 
The ovarian hormone oestradiol promotes neuritic outgrowth in different neuronal 
types, by mechanisms that remain elusive. Recent studies have shown that the Notch-
regulated transcription factor neurogenin 3 controls neuritogenesis. In this study we 
have assessed whether oestradiol regulates neurogenin 3 in primary hippocampal 
neurones. As expected, neuritogenesis was increased in the cultures treated with 
oestradiol. However, the neuritogenic action of oestradiol was not prevented by ICI 
182.780, an antagonist of classical oestrogen receptors. Oestradiol decreased the 
expression of Hairy and Enhancer of Split-1, a Notch-regulated gene that negatively 
controls the expression on neurogenin 3. Furthermore, oestradiol increased the 
expression of neurogenin 3 and regulated its distribution between the neuronal cell 
nucleus and the cytoplasm. The effect of oestradiol on neurogenin 3 expression was not 
blocked by antagonists of classical nuclear oestrogen receptor-mediated transcription 
and was not imitated by selective agonists of nuclear oestrogen receptors. In contrast, 
G1, a ligand of G protein receptor 30 / G protein-coupled oestrogen receptor, fully 
reproduced the effect of oestradiol on neuritogenesis, neurogenin 3 expression and 
neurogenin 3 subcellular localisation. Moreover, knockdown of neurogenin 3 in 
neurones by transfection with small interference RNA for neurogenin 3 completely 
abrogated the neuritogenic actions of oestradiol and G1. These results suggest that 
oestradiol regulates neurogenin 3 in primary hippocampal neurones by a non-classical 
steroid signalling mechanism, which involves the downregulation of Notch activity and 
the activation of G protein receptor 30 / G protein-coupled oestrogen receptor or of 
other unknown G1 targets. In addition, our findings indicate that neurogenin 3 
participates in the neuritogenic mechanisms of oestradiol in hippocampal neurones. 
  
 
Introduction 
Notch receptors (Notch 1 to 4, in vertebrates) are integral membrane proteins that bind 
to several different ligands, such as Delta 1, 3 and 4 and Jagged 1 and 2 (in mammals) 
(1). Upon ligand binding, Notch is proteolytically cleaved within its transmembrane 
domain by presenilin-1, the enzymatic component of the γ-secretase complex. The 
proteolysis of Notch results in the release of its active intracellular domain, which is 
translocated into the cell nucleus. Canonical Notch signalling involves the binding of 
Notch intracellular domain to DNA-binding cofactors and the subsequent activation of 
the transcription of target genes (1,2). 
  
In developing neurones Notch signalling is involved in the control of neurite extension 
and remodelling. The activation of Notch inhibits neurite outgrowth or causes their 
retraction, whereas inhibition of Notch 1 signalling promotes neurite extension (3,4). 
The activation of Notch in neuronal cultures from mice hippocampus results in a 
decrease in the number of dendrites and in an increase in their length. These effects are 
associated with an increase in the expression of  the transcription factors Hairy and 
Enhancer of Split (Hes)1 and Hes5 (5). In turn, Hes1 negatively controls the expression 
of a series of proneural genes from the bHLH superfamily, analogous of Achaete scute 
and Atonal (6). One of these genes is neurogenin 3 (Ngn3). The overexpression of Ngn3 
in cultured hippocampal neurones causes an increase in the number of dendrites and a 
transient decrease in the number of afferent GABAergic synaptic inputs, resulting in an 
increase in the ratio of excitation/inhibition and in an increase in neuronal activity (7).  
 
  
In contrast to Notch, oestradiol, as Ngn3, promotes axonal and dendritic outgrowth in 
the CNS (8). In addition, the effects of oestradiol on hippocampal neurones show some 
additional similarities with the effects of Ngn3. Thus, in CA1 pyramidal neurones 
oestradiol increases the density of both dendritic spines and axospinous synapses and 
decreases the activity of GABAergic synaptic inputs (9). The mechanism mediating the 
neuritogenic effects of oestradiol are still not well understood. Nevertheless, IGF-I 
receptor (10,11), TrkB receptor (12), cAMP/ protein kinase A (PKA) (13), PKC (14), 
Src/Ras/ERK signalling and cAMP-response element-binding protein (CREB) (14,15) 
have been shown to be involved in the hormonal neuritogenic effect in different 
neuronal types. Some of these signalling pathways that are regulated by oestradiol may 
interact with Notch signalling (16-18). Indeed, a recent study has shown that oestradiol 
downregulates Notch signalling in developing hippocampal neurones (19). Given the 
similarities between the neuritogenic effect of Ngn3 and oestradiol we hypothesise that 
oestradiol, by inhibition of Notch signalling, may increase the expression of Ngn3. Here 
we show that oestradiol promotes neuritogenesis in hippocampal neurones by an 
unclassical steroid signalling mechanism that involves the regulation of Ngn3. 
 
Materials and Methods 
Animals 
CD1 mice were raised in the Cajal Institute and used to generate embryos for this study. 
The day of vaginal plug was defined as E0. All procedures for handling and killing the 
animals used in this study were in accordance with the European Commission 
guidelines (86/609/CEE) and were approved by our institutional animal care and use 
committee. 
 
  
 
 
Hippocampal neuronal cultures and experimental treatments 
The hippocampus was dissected out from embryonic day 17 mouse embryos and 
dissociated to single cells after digestion with 0.5% trypsin (Worthington Biochemicals, 
Freehold, NJ) and DNase I (Sigma-Aldrich) at 37º C for 15 min and washed in 
Ca2+/Mg2+-free Hank's Buffered Salt Solution (20). Neurones were counted and plated 
on 6-wells plates or glass coverslips coated with poly-L-lysine (Sigma-Aldrich) at a 
density of 300-700 neurones/mm2, and they were cultured in phenol red free Neurobasal 
supplemented with B-27 and GlutaMAX I (Invitrogen, Crewe, United Kingdom). Under 
these conditions, glial growth should be reduced to less than 0.5% at 5 days in vitro 
(DIV) (21). Nevertheless we used cultures at 1 and 3 DIV and at these stages the level 
of astrocyte contamination was 5% at 1 DIV and 2% at 3 DIV, as judged by 
immunocytochemistry for glial fibrillary acidic protein (GFAP), neurone-specific βIII 
tubulin and DAPI nuclear staining.  
 
Cell treatments 
At 1 or 3 days in vitro (DIV) the culture medium was replaced for 2 h by fresh medium 
devoid of B27 and GlutaMAX I supplement. Then the cells were incubated for 2 h with 
one of the following test compounds, alone or in combination: 17β-oestradiol (10-8-10-
12M); the ER antagonist ICI 182.780 (10-8M; Sigma-Aldrich Co., St Louis, MO); the 
selective ERα agonist propylpyrazole triol (PPT; 10-8M; Tocris BioScience, Bristol, 
UK); the selective ERβ agonist diarylpropionitrile (DPN; 10-9M; Tocris); the selective 
ERα antagonist 1,3 - bis (4-hydroxyphenyl) - 4 - methyl - 5 - [4 - (2 - piperidinyl - 
ethoxy) phenol] - 1H -pyrazole dihydrochloride (MPP; 10-8M; Tocris); the selective 
  
ERβ antagonist 4 - [2 - phenyl - 5,7 - bis (trifluoromethyl) pyrazolo [1,5-a] pyrimidin - 
3 - yl] phenol (PHTPP; 10-8 M; Tocris) and the GPR30 agonist G1 (10-8 and 10-10M; 
Calbiochem, San Diego, CA). Test compounds were dissolved at 10-2M in ethanol and 
then to the final concentration in Neurobasal medium. For immunocytochemistry 
assays, the treatments were performed during 16 h, and cultures were not deprived of 
B27 and GlutaMAX I supplement.   
 
Inhibition of Ngn3 expression using small interfering RNAs  
Small interfering RNAs (siRNAs) oligonucleotides were purchased from Applied 
Biosystems/Ambion and the concentration was 25 nM during transfection. The 
following siRNAs were used: siRNA#1 targeting Ngn3 (sense, 
AACUACAUCUGGGCACUGAtt; antisense, UCAGUGCCCAGAUGUAGUUgt); 
siRNA#2 targeting Ngn3 (sense, GCUUCUCAUCGGUACCCUUtt; antisense, 
AAGGGUACCGAUGAGAAGCct). A non targeting siRNA was used as negative 
control.  
 
Neurones were co-transfected at 3 days in vitro (DIV) using the Effectene Transfection 
Reagent (Qiagen GmbH, Hilden, Germany), following the manufacturer’s instructions 
with pEGFP-C2 (Clontech, USA) plus one of the siRNA oligonucleotides targeted to 
Ngn3 or the siRNA negative control. After 16h of expression time the cultures were 
processed for immunostaining. The same plasmids and siRNAs were nucleofected into 
cultured neurones using an Amaxa nucleofector with the Mouse Neurone Kit (Amaxa, 
Gaithersburg, MD) according to the manufacturer's instructions and after 1 DIV, the 
neurones were harvested and processed for real time PCR analysis. 
 
  
Analysis of gene expression by quantitative real-time polymerase chain reaction 
(q-PCR) 
Total RNA was extracted from cultures with illustra RNAspin Mini RNA isolation kit 
from GE Healthcare (Buckinghamshire, UK). First strand cDNA was prepared from 
RNA using the First Strand Synthesis kit from Fermentas GMBH (St Leon-Rot, 
Germany) following the manufacturer instructions. Quantitative real-time PCR was 
performed using the ABI Prism 7000 Sequence Detector (Applied Biosystems, 
Weiterstadt, Germany). TaqMan probes and primers for Ngn3, Hes1 and for the control 
housekeeping gene, Gapdh, were Assay-on-Demand gene expression products (Applied 
Biosystems). Primer sequences for Gpr30 were designed using Primer Express (AB) 
and were: forward, 5’- TGCTGCCATCCAGATTCAAG -3’ and reverse, 5’-
GGGAACGTAGGCTATGGAAAGAA-3’. Real-time PCRs were performed following 
the suppliers instructions using the TaqMan or Sybr Green Universal PCR Master Mix. 
All reactions were done in triplicates, from 3 different cultures. Ngn3, Hes1 and Gpr30 
expression was normalised for Gapdh expression.  
 
Immunocytochemistry 
Cells were fixed for 20 min at room temperature in 4% paraformaldehyde and 
permeabilised for 4 min with 0.12% Triton-X plus 0.12% gelatine in phosphate buffered 
saline (PBS). Cells were then washed with PBS/gelatine and incubated for 1 h with anti-
GFAP rabbit polyclonal antibody (DakoCytomation, Milno, Italy; diluted 1:500 in 
PBS/gelatine), with anti-βIII tubulin mouse monoclonal antibody (TUJ1; COVANCE, 
Emeryville, CA; diluted 1:1000 in PBS/gelatine), with anti-Ngn3 mouse monoclonal 
antibody (F25A1B3; developed by Ole D. Madsen and obtained from the NICHD 
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA; diluted 
  
1:2000 in PBS/gelatine) or with goat anti-GFP (Abcam, Cambridge, UK; diluted 1:1000 
in PBS/gelatine). After washing in the same buffer, cells were incubated for 1h at room 
temperature with goat anti mouse Cy2 (Jackson ImmunoResearch Europe Ltd, 
Newmarket, Suffolk, England, diluted 1:1000) for the detection of βIII tubulin; with 
anti-mouse-biotin antibody followed by streptavidin-peroxidase (Jackson), Tyramide 
(Perkin-Elmer Life Sciences, Boston, MA) and Alexa 568-streptavidin (Molecular 
Probes, Invitrogen, Barcelona, Spain) for the detection of Ngn3 or Alexa 488-donkey 
anti goat (Molecular Probes, diluted 1/500) for detection of GFP. Cell nuclei were 
stained with DAPI.  
 
Analysis of neuritogenesis  
To assess the effect of oestradiol and G1 on neuritogenesis the number of primary βIII 
tubulin-immunoreactive neurites was counted at 1 DIV at a magnification of 400X. The 
number of primary neurites was counted in 50 to 70 cells per experimental condition. In 
addition, the neuritic arbour was assessed at 3 DIV by the method of SHOLL (22) using 
a grid of 6 concentric circles with increasing radius of 20 μm. The grid was 
superimposed to the images of βIII tubulin-immunoreactive neurones at a magnification 
of 400X, placing the innermost circle over the perikaryon. The number of neurites 
intersecting each circle was counted in 50 to 70 cells per experimental condition. 
 
Analysis of Ngn3 subcellular distribution 
In order to assess Ngn3 subcellular distribution by immunocytochemistry, confocal 
analysis was performed in a Leica (Bensheim, Germany) microscope. Images were 
acquired digitally using a 40x oil immersion objective and fluorescence filters. 
Randomly selected fields containing cells counterstained with DAPI were digitalised, 
  
and the Mean Gray Value for Ngn3 immunostaining in the nuclei and cytoplasm areas 
was measured using ImageJ 1.37v software (freely available at the National Institutes of 
Health: rsbweb.nih.gov/ij/). The values were background subtracted using the average 
Mean Gray Value of the preparation background in each of the experimental conditions 
and data were represented as relative fluorescence intensity of nucleus versus cytoplasm 
of each neurone. Subcellular distribution of Ngn3 was assessed in 25 to 52 neurones for 
each experimental condition.  
 
Statistical analysis 
Statistical significance between two groups was assessed by student t-test and between 
more than two groups by one-way analysis of variance (ANOVA) followed by the 
Bonferroni correction, using GraphPad Prism 5 (GraphPad Software, Inc., San Diego, 
CA). The levels of significance were denoted as *, # p < 0.05, **, ##p < 0.01, ***, 
###p < 0.001. The number used for statistical analysis was the number of independent 
experiments. Data in the figures are the results of 3 independent experiments (n=3), 
except for figures 1 and 2 in which n=4. Data are represented as mean + SEM. 
 
Results 
Oestradiol promotes neuritogenesis of hippocampal neurones in primary cultures 
The first experiment was designed to confirm the neuritogenic effect of oestradiol in our 
model system. We selected neuronal cultures at 1 and 3 DIV because these 
developmental stages correspond to neurite outgrowth and dendritic branching, 
respectively. As shown in Fig. 1, oestradiol significantly increased the number of 
primary neurites in hippocampal neurones at 1 DIV and the number of intersections of 
the neurites with the lines of the grid used for Sholl analysis at 3 DIV. 
  
 
Oestradiol reduces Hes1 expression and enhances Ngn3 expression in hippocampal 
neurones  
In a second experiment we assessed whether oestradiol regulates the expression of the 
neuritogenic transcription factor Ngn3 and of the transcription factor Hes1, which 
mediates the effect of Notch on Ngn3 expression. Oestradiol, at doses of 10-12 to 10-8M, 
significantly decreased Hes1 mRNA levels (Fig. 2A) and significantly increased Ngn3 
mRNA levels (Fig. 2B).  
 
Oestradiol regulates the subcellular localisation of Ngn3 in hippocampal neurones 
Previous studies have shown that Ngn3 in hippocampal neurones is translocated from 
the cell nucleus to the cytoplasm at the moment of the initiation of neurite development 
and then from the cytoplasm back to the cell nucleus at the end of the differentiation 
process (23). In agreement with these previous findings we observed more Ngn3 
immunoreactivity in the cell nucleus of control neurones at 1 DIV, before the initiation 
of neurite development, than at 3 DIV, when neurite development is initiated (Fig. 3). 
Oestradiol increased the cytoplasmic localisation of Ngn3 at 1 DIV and the nuclear 
localisation of Ngn3 at 3 DIV (Fig. 3). 
 
Classical nuclear oestrogen receptor signalling is not involved in the effect of 
oestradiol on Ngn3 expression 
To determine whether the effect of oestradiol on Ngn3 expression was mediated by 
classical transcriptional regulation by oestrogen receptors (ERs), the cultures were 
treated with PPT and DPN, selective agonists of ERα and ERβ mediated transcription, 
  
respectively. Neither PPT nor DPN, tested separately or in combination, were able to 
significantly affect the mRNA levels of Ngn3 (Fig. 4A,B).  
 
To further explore the role of ER-mediated transcription on the effect of oestradiol, the 
cultures were exposed to the hormone in presence of ICI 182,780 (ICI), an antagonist of 
both ERα and ERβ mediated transcription. ICI, tested at a dose of 10-8M, did not 
prevent the effect of oestradiol on Ngn3 mRNA levels (Fig. 4C,D). On the contrary, ICI 
per se significantly increased the mRNA levels of Ngn3 (Fig. 4C,D). Then, we tested 
the effect of MPP and PHTPP, selective antagonists of ERα and ERβ mediated 
transcription, respectively. Neither MPP nor PHTPP were able to block the effect of 
oestradiol on Ngn3 mRNA levels (Fig. 4E,F). In addition, MPP per se significantly 
increased the mRNA levels of Ngn3 at 1 DIV and PHTPP significantly increased the 
effect of oestradiol on Ngn3 levels at 3 DIV.  
 
Classical nuclear oestrogen receptor signalling is not involved in the effect of 
oestradiol on neuritogenesis 
The previous findings suggest that oestradiol regulates Ngn3 by a mechanism 
independent of classical ER mediated transcription. Thus, we assessed whether classical 
ERs are involved in the regulation of neuritogenesis by oestradiol in our model. 
Neuronal cultures were treated for 3 hours with vehicle, 10-10 M 17β-oestradiol or 10-10 
M 17β-oestradiol in presence of 10-8 M ICI. As shown in figure 5, ICI did not affect the 
neuritogenic effect of oestradiol.  
 
  
G1, a ligand of GPR30/GPER, mimics the effect of oestradiol on neuritogenesis, 
Ngn3 expression and Ngn3 subcellular localisation  
Since the previous results suggested that oestradiol is regulating Ngn3 expression and 
neuritogenesis in hippocampal neurons by a mechanism independent of classical ER 
mediated transcription, we examined the effect of G1, a ligand of GPR30/GPER, which 
is a putative membrane oestrogen receptor. First, we confirmed that Gpr30/Gper mRNA 
is expressed in the cultures of hippocampal neurones (Fig. 6A). No significant 
differences were observed in Gpr30/Gper mRNA levels between 1 DIV and 3 DIV. The 
treatment of the cultures with G1 increased the mRNA levels of Ngn3 in a dose-
dependent manner at 1 and 3 DIV (Fig. 6B). In addition, G1 increased the number of 
primary neurites at 1 DIV and the number of intersections of the neurites with the lines 
of the grid used for Sholl analysis at 3 DIV (Fig. 6C,D). Finally, G1 also reproduced the 
effect of oestradiol on Ngn3 subcellular localisation at 1 and 3 DIV (Fig. 7). 
 
Downregulation of Ngn3 with specific siRNAs blocks the effects of oestradiol and 
G1 on neuritogenesis of cultured hippocampal neurones 
To assess whether Ngn3 mediates the effects of oestradiol and G1 on neuronal 
morphology, two different double-stranded siRNA oligonucleotides targeting Ngn3 
(siRNA#1, siRNA#2) were electroporated in hippocampal neuronal cultures. A non 
targeting siRNA was used as control. Fig. 8A shows that both siRNAs targeting Ngn3 
significantly reduced Ngn3 mRNA expression in comparison to the control siRNA. 
Next we added oestradiol and G1 to cultures co-transfected with pEGFP-C2 plus either 
control siRNA, siRNA#1 or siRNA#2 and we analyzed the morphology of hippocampal 
neurones. Fig. 8B,C shows that Ngn3-specific siRNA oligonucleotides, per se, induced 
a decrease in dendritic tree complexity as evaluated by Sholl method. In addition, 
  
oestradiol and G1 induced an increase in dendritic tree complexity in cultures 
transfected with the control siRNA, but not in the cultures transfected with Ngn3-
specific siRNA oligonucleotides. 
 
Discussion 
In agreement with previous findings in different in vitro and in vivo experimental 
models and different neuronal cell types (8,10-15,24), our present results confirm that 
oestradiol promotes neuritogenesis in primary hippocampal neurones from mice. To 
further explore the mechanisms involved in the neuritogenic effect of oestradiol, we 
have assessed in this study the effect of the hormone on the expression of Ngn3, a 
proneural gene that is regulated by Notch activity and that is involved in the control of 
dendrite morphology and synaptic plasticity of cultured hippocampal neurones (5,7,23).  
 
The findings of the present study indicate that oestradiol increases the expression of 
Ngn3 in developing hippocampal cultures. Since the vast majority of cells in these 
cultures are neurones, the effect of ostradiol is most probably on neuronal Ngn3.  The 
effect of oestradiol on Ngn3 expression was more pronounced at 3 DIV than at 1 DIV. 
This may be due to the fact that basal Ngn3 expression levels are higher at 1 DIV than 
at 3 DIV (23). Thus, under conditions of high basal Ngn3 expression levels, the effect of 
oestradiol may be less evident than under conditions of low Ngn3 levels. However, 
other alternatives, including possible developmental changes in the expression or 
activity of oestradiol-regulated intracellular signalling molecules, can not be excluded.  
 
In parallel to the effect of oestradiol on the expression of Ngn3, the hormone also 
regulates its subcellular localisation in hippocampal neurones, promoting its 
  
translocation from the cell nucleus to the cytoplasm at 1 DIV and from the cytoplasm to 
the cell nucleus at 3 DIV. These modifications in the subcellular localisation of Ngn3 
are observed during the normal differentiation of hippocampal neurones and are 
associated with the initiation of neurite development (movement from the nucleus to the 
cytoplasm) and with the end of the differentiation process (movement from the 
cytoplasm back to the nucleus) (23). Therefore, the effect of oestradiol on Ngn3 
subcellular localisation is compatible with a hormonally-induced acceleration of 
neuronal differentiation. 
 
Since Ngn3 expression and subcellular localisation in developing hippocampal neurones 
is regulated by Notch signalling (5,7,23), we assessed the effect of oestradiol on Hes1, 
one of the primary effectors of Notch in developing hippocampal neurones (5). Our 
findings, showing that oestradiol decreases Hes1 expression, are in agreement with 
previous results showing that oestradiol downregulates Notch signalling in developing 
hippocampal neurones (19).  
 
To further analyse the mechanisms involved in the regulation of Ngn3 by oestradiol, we 
assessed several compounds that act as promoters or inhibitors of ERα and ERβ 
mediated transcription. ICI 182,780 (ICI), an antagonist of both ERα and ERβ mediated 
transcription was unable to block the effect of oestradiol on Ngn3 expression. 
Interestingly, ICI was also unable to block the neuritogenic effect of oestradiol. 
Although ICI has been shown to block the neuritogenic effect of oestradiol in several 
neuronal types, such as hypothalamic neurones, dorsal root ganglion cells and PC12 
cells (10,11,25), other studies have shown that ICI does not block oestrogenic effects on 
neuritogenesis in mouse midbrain dopaminergic neurones (13) and in male rat 
  
hypothalamic neurones incubated with oestradiol added to medium conditioned by 
astroglia derived from ventral mesencephalon (26,27). This suggests that oestradiol may 
activate different signalling mechanisms to induce neuritogenesis depending on the 
neuronal type or the culture conditions. Glial support of oestradiol-induced neurite 
outgrowth (26,27) exerted by the 2-5% of astrocyes present in our cultures could 
explain why ICI failed to block oestradiol effects. Nevertheless, our findings are in 
agreement with previous results showing that ICI does not block oestrogen induced 
neuritogenesis in hippocampal neurones in vitro (28). In addition, ICI increased Ngn3 
expression as oestradiol did. This result is in agreement with previous findings showing 
that ICI has some estrogenic effects on hippocampal neurones and regulates the 
phosphorylation of ERK1, ERK2 and Akt and the expression of spinophillin and Bcl-2 
in a similar manner than oestradiol (29). In contrast, PPT and DPN, selective agonists of 
ERα and ERβ mediated transcription, respectively, were not able to imitate the effect of 
oestradiol on Ngn3 expression. Furthermore, MPP and PHTPP, selective antagonists of 
ERα and ERβ mediated transcription, respectively, were not able to antagonise the 
effect of oestradiol on Ngn3 expression and even imitated (MPP) or potentiated 
(PHTPP) the effect of oestradiol. All these findings suggest that the hormone is 
regulating Ngn3 expression by a non-canonical mechanism, which probably is 
independent of classical nuclear ER mediated transcription.  
 
GPR30, also known as G protein-coupled oestrogen receptor (GPER), is a putative 
membrane associated ER. Although there is considerable debate on whether GPR30 is 
or not acting as an ER (30-33), there is evidence that G1, a ligand of GPR30, imitate the 
effects of oestradiol in different cell types and tissues (34,35). Our results are 
compatible with an action of oestradiol through GPR30. Indeed, the oestradiol 
  
concentration range used in our experiments fits with its reported affinity for GPR30, 
with an EC50 value of approximately 0.5 nM (36). Besides, it has been recently shown 
that in breast cancer SK-BR-3 cells, G1 may bind to the ERα36 variant of ERα, whose 
expression is increased by GPR30 (37). Whatever the mechanism of action of G1 is, our 
findings indicate that this compound is able to fully reproduce the effect of oestradiol on 
neuritogenesis, Ngn3 expression and Ngn3 subcellular localisation. Moreover the 
neuritogenic actions of oestradiol and G1 are blocked when Ngn3 expression is 
downregulated by specific siRNA. These results suggest that oestradiol and G1 may act 
through common mechanisms to regulate Ngn3 expression. In addition, our findings 
also suggest that Ngn3 mediates the effect of oestradiol and G1 on the development of 
hippocampal neurones. 
 
In conclusion, our findings suggest that oestradiol regulates neuritogenesis in primary 
hippocampal neurones by a non-classical steroid signalling mechanism that involves the 
activation of G1 molecular targets, the downregulation of Notch activity and the 
upregulation of Ngn3 expression. 
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Figure legends 
Figure 1, Effect of 17β-oestradiol on the morphology of hippocampal neurones in 
culture. Neurones from E17 mouse hippocampi were plated at an initial cell density of 
300/mm2. After 1 or 3 days in vitro (DIV), 17β-oestradiol (17βE, 10-10 M) or vehicle 
were added for 16 h and cultures were prepared for immunofluorescence analysis. (A) 
Representative fluorescence images of hippocampal neurones immunostained for βIII-
tubulin (green) with cell nuclei stained with DAPI (blue). (B) Results of morphometric 
evaluation. The graphs show the number of primary neurites at 1 DIV and the number 
of intersections of the neurites with the lines of the grid used for Sholl analysis at 3 
DIV. A total of 50 to 70 cells were assessed from each experimental group. Data are 
mean + SEM. The n used for statistical analysis was the number of independent 
experiments (n=4). Significance levels were determined using an unpaired t-test. *** 
p<0.001 versus control values.  
 
Figure 2, HES1 and Ngn3 mRNA levels are significantly modified in hippocampal 
neuronal cultures treated with 17β-oestradiol. Neurones from E17 mouse 
hippocampi were plated at an initial cell density of 300/mm2. After 1 day in vitro (DIV), 
17β-oestradiol (17βE, 10-12 M to 10-8 M) or vehicle were added for 2h and cells were 
harvested for RNA extraction. The mRNA levels of Hes1 (A) and Ngn3 (B) were 
measured on cell lysates by real time RT-PCR. Data represent the mean+SEM and are 
expressed as percentage of control values. Asterisks indicate statistical differences in 
comparison to control values (*, p<0.05; **, p<0.01; ***, p<0.001) as determined using 
one-way analysis of variance (ANOVA) followed by the Bonferroni correction. 
 
  
Figure 3, Oestradiol regulates the subcellular distribution of Ngn3 during the 
development of hippocampal neurones. Cultured hippocampal neurones untreated or 
treated with 17β-oestradiol (17βE, 10-10 M) were fixed at 1 and 3 DIV and fluorescence 
was analysed for Ngn3 immunostaining (red) and the nuclear marker DAPI (blue). (A) 
Representative micrographs of control and oestradiol treated neurones. Magenta colour 
in the cell nucleus is due to colocalisation of Ngn3 and DAPI. (B) Quantification of the 
subcellular localisation of Ngn3 in the cell nucleus and the cytoplasm. Randomly 
selected fields containing cells counterstained with DAPI were digitalised and the Mean 
Gray Value for Ngn3 immunostaining was measured in the cell nucleus and the 
cytoplasm using ImageJ 1.37v software. The graphs show the mean + SEM of the 
relative fluorescence intensity in nuclei versus cytoplasm. A total of 25 to 52 cells were 
assessed for each experimental group. The n used for statistical analysis was the number 
of independent experiments (n=3). Significance levels were determined using two way 
ANOVA followed by the Bonferroni correction. ***, **, statistical differences for the 
data sets connected by horizontal lines (***p<0.001, **p<0.01); ###, statistical 
differences in comparison to control cultures at 1 DIV (p < 0.001); ^^, statistical 
differences in comparison to control cultures at 3 DIV (p < 0.01). 
 
Figure 4, Effect of agonists and antagonists of classical oestrogen receptors on 
Ngn3 mRNA levels. Neuronal cultures were treated for 3 hours with vehicle (Control), 
10-10 M 17β-oestradiol (17βE), 10-8 M PPT (ERα agonist), 10-9 M DPN (ERβ agonist), 
10-8 M ICI 182,780 (ICI; ERα and ERβ antagonist), 10-7 M MPP (ERα antagonist) or 
10-7 M PHTPP (ERβ antagonist) at 1 DIV (A,C,E) and 3 DIV (B,D,F) . Graphs show 
Ngn3 mRNA levels in cell lysates. Data represent the mean+SEM. *,**,*** statistical 
differences (*p < 0.05, **p < 0.01, ***p<0.001) in comparison to the values of control 
  
cultures; ###, statistical differences (p < 0.001) in comparison to cultures treated with 
17β-oestradiol. 
 
Figure 5, The oestrogen receptor antagonist ICI 182,780 does not block the effect 
of oestradiol on neuritogenesis. Neuronal cultures at 1 DIV were treated for 16 hours 
with vehicle (Control), 17β-oestradiol (17βE) or 17βE and ICI 182,780 (ICI). The graph 
shows the number of primary neurites. Data represent the mean+SEM. A total of 60 to 
80 cells were assessed from each experimental group. The n used for statistical analysis 
was the number of independent experiments (n=3). Significance levels were determined 
using two way ANOVA followed by the Bonferroni correction. *** statistical 
difference (***p<0.001) in comparison to the values of control cultures. 
 
Figure 6, Effect of G1 on hippocampal neurones in culture. Neurones from E17 
mouse hippocampi were plated at an initial cell density of 300/mm2. After 1 or 3 DIV, 
G1 (10-10 M or 10-8 M) or vehicle were added for 2h or 16 h and cells were harvested 
for RNA extraction or prepared for immunofluorescence analysis, respectively. (A) 
GPR30 mRNA expression in control cultures at 1 and 3 DIV. (B) Effect of G1 
treatment on Ngn3 mRNA levels in hippocampal neuronal cultures at 1 and 3 DIV. Data 
represent the mean+SEM and are expressed as percentage of control values. Asterisks 
indicate statistical differences in comparison to control values (*, p<0.05; **, p<0.01; 
***, p<0.001) as determined using one-way analysis of variance (ANOVA) followed by 
the Bonferroni correction. (C) Representative fluorescence images of hippocampal 
neurones immunostained for βIII-tubulin (green) and the nuclear marker DAPI (blue). 
(D) Results of the morphometric evaluation of the number of primary neurites at 1 DIV 
and the number of intersections of the neurites with the lines of the grid used for Sholl 
  
analysis at 3 DIV. A total of 50 to 70 cells were assessed for each experimental group. 
The n used for statistical analysis was the number of independent experiments. 
Significance levels were determined using an unpaired t-test. * p<0.05, *** p<0.001 
versus control values.  
  
Figure 7, G1 regulates the subcellular distribution of Ngn3 during the development 
of hippocampal neurones. Cultured hippocampal neurones untreated or treated with 
G1 (10-10 M) were fixed at 1 and 3 DIV and fluorescence was analysed for Ngn3 
immunostaining (red) and the nuclear marker DAPI (blue). (A) Representative 
micrographs of control and G1 treated neurones. (B) Quantification of the subcellular 
localisation of Ngn3 in nuclei and cytoplasm of neurones. The graphs show the mean + 
SEM of the relative fluorescence intensity in nuclei versus cytoplasm. A total of 52 cells 
were counted for each experimental group. The n used for statistical analysis was the 
number of independent experiments (n=3). Significance levels were determined using 
two way ANOVA followed by the Bonferroni correction. ***, statistical differences for 
the data sets connected by horizontal lines (p<0.001); ###, statistical differences in 
comparison to control cultures at 1 DIV (p < 0.001); ^^^, statistical differences in 
comparison to control cultures at 3 DIV (p < 0.001). 
 
Figure 8, Downregulation of Ngn3 expression impairs the effects of 17β-oestradiol 
and G1 on the morphology of hippocampal neurones in culture. (A) Effects of 
siRNAs on the levels of Ngn3 mRNA expression. Dissociated E17 hippocampal cells 
were nucleofected with siRNAs targeting Ngn3 (siRNA#1, siRNA#2) and non targeting 
siRNA (negative control, NC) using an Amaxa nucleofector with the Mouse Neuron 
Kit. After 1 DIV, cells were harvested and processed to real time PCR analysis. Data are 
  
mean ±SEM. Significance levels were determined using two way ANOVA followed by 
the Bonferroni correction. *** p<0.001 versus negative control. (B) Hippocampal 
neuronal cultures were co-transfected at 3 DIV with pEGFP-C2 plus non targeting 
siRNA or one of the siRNA oligonucleotides targeted to Ngn3 and were untreated or 
treated with 17β-oestradiol and G1. After 16 hours cultures were fixed and processed 
for GFP immunostaining (green); nuclei were marked with DAPI (blue). (C) Results of 
the morphometric evaluation. The graphs show the number of intersections of the 
neurites with the lines of the grid used for Sholl analysis at 3 DIV. A total of 30 to 50 
cells were assessed from each experimental group. Data are mean + SEM. The n used 
for statistical analysis was the number of independent experiments (n=4). Significance 
levels were determined using an unpaired t-test. *** p<0.001 versus untreated negative 
control value; nd, no differences between bars connected by horizontal lines.     
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
